Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

Stopped Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern.

Conditions

• Type 2 Diabetes Mellitus
• Renal Impairment

Interventions

• DRUG: Insulin glargine 300 U/mL
• DRUG: Insulin degludec 100 U/mL

Sponsor

Sanofi